New dosing strategy for Triple-Negative breast cancer drug shows promise
NCT ID NCT06926920
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer that has not responded to prior treatments. The goal is to see if the new dosing is safer and works better at shrinking tumors or slowing cancer growth. About 100 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
John Flynn Private Hospital
RECRUITINGTugun, Queensland, 4224, Australia
-
Los Angeles Cancer Network (LACN) - Good Sam
RECRUITINGLos Angeles, California, 90017, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
NOT_YET_RECRUITINGSeoul, 03722, South Korea
-
Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63110, United States
-
St. Vincent's Hospital - Kinghorn Cancer Center
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
Sunshine Coast University Private Hospital
RECRUITINGBirtinya, Queensland, 4575, Australia
-
Tennessee Oncology, PLLC
RECRUITINGNashville, Tennessee, 37203, United States
-
Texas Oncology - DFW
RECRUITINGDallas, Texas, 75246, United States
-
The University of Kansas Hospital
RECRUITINGWestwood, Kansas, 66205, United States
-
Virginia Oncology Associates
RECRUITINGNorfolk, Virginia, 23502, United States
-
West Cancer Centre
RECRUITINGGermantown, Tennessee, 38138, United States
-
Winship Cancer Institute - Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.